Guggenheim Reiterates Buy Rating for Larimar Therapeutics (NASDAQ:LRMR)
Larimar Therapeutics (NASDAQ:LRMR – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Guggenheim in a note issued to investors on Tuesday,Benzinga reports. They presently have a $26.00 target price on the stock. Several other equities research analysts have also recently commented on LRMR. Citigroup restated a “buy” rating on shares of […]
Larimar Therapeutics (NASDAQ:LRMR – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Guggenheim in a note issued to investors on Tuesday,Benzinga reports. They presently have a $26.00 target price on the stock. Several other equities research analysts have also recently commented on LRMR. Citigroup restated a “buy” rating on shares of […]
